New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:05 EDTANXAdventrx initiates QT/QTc clinical study of ANX-188
ADVENTRX Pharmaceuticals announced that it has initiated dosing in a thorough QT/QTc study of ANX-188. The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers. The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial. Sixty subjects will be enrolled. Each subject will receive each of four treatments during each of the four treatment periods.
News For ANX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ANX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use